← Leaderboards
Rakesh K Goyal
Children'S Hosp Pittsburgh/Upmc Hlth Sys
$336,381
Attributed
$336,381
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $164.4K · FY2005–08$200K$150K$100K$50K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$336,381 · 3
By mechanism
R21$317,291 · 1
M01$19,090 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “5&Apos”
- Jonathan L. Haines · Doheny Eye Institute$18,006,454
- Eric M Reiman · Banner Health$17,602,936
- William S Kremen · University Of California Davis$12,642,693
- Sudha Seshadri · Boston University Medical Campus$11,197,981
- Ming-Hui Zou · University Of Tennessee Knoxville$10,519,909
- Helena Chang Chui · University Of Pennsylvania$8,770,076
Research focus
5&AposGenotypeCohortAdverse EffectsGene ExpressionGenesBone Marrow TransplantationChemotherapyChildAra-CChildhood Acute Myeloid LeukemiaAdultAdolescentClinical Trials, Phase IiiFlanking RegionCyclin-Dependent KinasesCytidine DeaminaseDatabasesDeoxycytidine KinaseDna ResequencingChildhoodEnzymesEvaluationHaplotypes
Grant awards (5)
Variation in Ara-C Pathway Genes and Treatment Outcomes in AML$152,926
R21 · FY2008 · CA · contact PI
Variation in Ara-C Pathway Genes and Treatment Outcomes in AML$164,365
R21 · FY2007 · CA · contact PI
BONE MINERAL DENSITY IN PATIENTS RECEIVING CORTICOSTEROIDS FOR CHILDHOOD LEUKEMI$15,943
M01 · FY2005 · RR
COG-AAML0123: A PHASE II STUDY OF GLEEVEC IN PH+ CHRONIC MYELOGENOUS LEUKEMIA$1,063
M01 · FY2005 · RR
COG-AAML0123: A Phase II Study of Gleevec in PH+ Chronic Myelogenous Leukemia$2,084
M01 · FY2004 · RR